This week’s Psychedelic Spotlight is Entheon Biomedical. Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule.

What’s your company vision?

Entheon is utilizing proprietary science, research and methodology to ensure addiction and mental health challenges no longer seem like an impossible, unending road.

Our vision is to ensure that when you or your loved one goes into recovery, you fully expect it will work; redefining the expectations of addiction treatment.

Why was your company started?

Entheon Biomedical was founded in 2019 as a response to the lack of effective treatment solutions for addiction disorders, and as a result of the established and growing research and clinical validation of psychedelic-assisted psychotherapy.

As we see it there is a major need for effective addiction and
mental health treatments; meanwhile, psychedelics are remerging within this “third renaissance” as a very impressive therapeutic candidate for a wide variety of indications, from depression to PTSD; addiction and eating disorders, to stroke rehabilitation and the ease of suffering for end-of-life and terminally-ill patients.

Entheon is working to conduct research and development to bridge the gap between the increasing societal need for effective therapies and the potential of psychedelics when administered in the optimum environment under medical supervision and support.

What’s been the biggest challenge so far?

After decades of intentional propaganda and well-disseminated falsehoods related to psychedelic compounds and their potential, one challenge has been turning the tide of public and investor perception toward psychedelic use. That being said, a phenomenal and expanding research, business, and education community has quickly grown demonstrating how psychedelic medicines have the potential to address and remedy some of the greatest human health challenges of our time. In the last two years, we have witnessed a major groundswell in support of psychedelics and are confident this trend is going to continue, resulting in increased access and availability.

What excites you most?

The opportunity to merge psychedelic-assisted psychotherapy, and specifically DMT-assisted therapy, with the newest innovations in EEG, genetic testing, machine learning, and AI in order to develop a personalized system of psychedelic medicine that treats patients in a highly specific and intelligent manner.

As a society, we are at the vanguard of a rapidly shifting approach as to how we view and address mental health and addiction disorders. Up until now, psychiatry, mental health, and addiction treatment have relied on objective standards and “one-size-fits-all” treatments, resulting in a system that lacks humanity and efficacy.

Psychedelic medicine paired with technology that works to better characterize the challenges of a particular patient will provide us with the opportunity to recreate this system and to develop therapies that put the individual at the center of their care regime.

What is your biggest lesson learned when raising capital?

The power of an authentic story: having a strong and indispensable reason for needing to fund a project, and of course backing that up with a capable team, a strong operational framework, and a roadmap to building value and return.

Did you notice any type of investor differences while raising money?

Many investors we spoke to early-on right up until the present day seemed to have a vested interest in what we were developing as a company. Most people have in some way been adversely affected by addiction, either themselves or through the suffering of a loved one. So for them, the fact that we as a company are very committed and engaged in developing effective treatment options for addiction really resonated. These are investors who see a major problem in modern society in the form of increasing addiction and overdose rates, one that is growing with the year, and are wanting to put their money behind therapies that have the potential to turn the tide.

Describe your business model in 10 words or less

Harnessing DMT & technology to remedy the underlying cause of addiction.

What tips would you give founders entering fundraising?

Be as prepared as possible to clearly outline the problem or market lack you are addressing, and be equally prepared to prove out how you are going to do what you say.

Remember, there is a lot of money out there, a lot of different
groups looking for good opportunities. Find the funds, VCs, family offices and investors with who you get on well and from there work to develop relationships. Investing in a pre-revenue or early-stage company is a major risk for these folks. Trust and confidence are essential but remember, like any positive and dynamic relationship it has to be a two-way street. There is a lot that founders and an early-stage organization can get out of investors beyond money, including support and strategic direction, so try to find fundraisers who are really into your mission and want to support it in any way possible.


We’d like to thank Entheon Biomedical for being a part of the Psychedelic Spotlight series. Stay tuned for weekly profiles on leaders in the psychedelic industry, and check out the Psychedelic Directory to learn more about Entheon Biomedical.

The post Psychedelic Spotlight: Entheon Biomedical appeared first on Microdose Psychedelic Insights.

Previous articleMassachusetts Legislators Introduce Bills to Study Psychedelics, Remove Criminal Penalties
Next articleField Trip Health Announces $50 Million Bought Deal Offering of Common Shares